Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

Gemcitabine is the first-line treatment for locally advanced and metastatic gallbladder cancer (GBC), but poor gemcitabine response is universal. Here, we utilize a genome-wide CRISPR screen to identify that loss of ELP5 reduces the gemcitabine-induced apoptosis in GBC cells in a P53-dependent manne...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Sunwang, Zhan, Ming, Jiang, Cen, He, Min, Yang, Linhua, Shen, Hui, Huang, Shuai, Huang, Xince, Lin, Ruirong, Shi, Yongheng, Liu, Qiang, Chen, Wei, Mohan, Man, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889377/
https://www.ncbi.nlm.nih.gov/pubmed/31792210
http://dx.doi.org/10.1038/s41467-019-13420-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889377/
https://www.ncbi.nlm.nih.gov/pubmed/31792210
http://dx.doi.org/10.1038/s41467-019-13420-x

Ejemplares similares